Armata Pharmaceuticals (ARMP) Q1 2025 earnings summary

Executive summary

• Focused on developing bacteriophage therapeutics for antibiotic-resistant bacterial infections, with lead candidates AP-PA02 and AP-SA02 advancing through late-stage clinical trials.

• Completed three Phase 2 trials; recent positive results from the Tailwind study for AP-PA02 in non-cystic fibrosis bronchiectasis and completed Phase 1b/2a diSArm study for AP-SA02 in S. aureus bacteremia, with topline results expected in Q2 2025.

• Secured $4.65 million in non-dilutive funding from MTEC/DoD and entered a $10 million secured credit agreement, extending debt maturities to March 2026.

• Advanced bacteriophage science through presentations and publications, including at the 7th Annual Bacteriophage Therapy Summit.

Financial highlights

• Grant and award revenue was $0.5 million for Q1 2025, down from $1.0 million in Q1 2024.

• Net loss for Q1 2025 was $6.5 million, a significant improvement from $25.0 million in Q1 2024, aided by a $5.2 million non-cash gain from convertible loan fair value changes.

• Operating expenses decreased 22% year-over-year to $8.7 million, with R&D expenses at $5.4 million and G&A expenses at $3.3 million.

• Cash and cash equivalents totaled $11.7 million as of March 31, 2025, up from $9.3 million at year-end 2024.

• Cash used in operating activities was $7.6 million for Q1 2025, compared to $10.6 million in Q1 2024.

Outlook and guidance

• Current cash is insufficient to fund operations for the next 12 months, raising substantial doubt about the ability to continue as a going concern.

• Plans to raise additional capital through equity, debt, or strategic arrangements; future funding needs depend on R&D progress and clinical trial costs.

• Topline data from the Phase 1b/2a diSArm study for AP-SA02 expected in the first half of 2025 to inform a potential pivotal trial.

• Additional DoD funding will support Phase 2a study close-out and preparation for an end-of-Phase 2 FDA meeting.